1. Although capecitabine or XELOX did not improve overall survival when compared to PF, efficacy was comparable suggesting single-agent capecitabine ...
1. Progression-free survival was greater in the trastuzumab group compared to standard care (17.8 months vs. 6.9 months). 2. Drug-related ...
Click to read this study in JAMA Oncology.
Click to read this study in Journal of Clinical Oncology.
Click to read this study in JAMA Oncology.
1. Progression-free survival is longer in those treated with capecitabine maintenance therapy as compared with best supportive care 2. Adverse ...
1. Atezolizumab plus capecitabine + bevacizumab performed marginally better with regards to progression free survival in patients with metastatic colorectal ...
Click to read the study in The Lancet Oncology.
1. Progression-free survival was extended by the use capecitabine as compared to active monitoring, but at the expense of increased ...
Click to read the study in JAMA Oncology.
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
